triapin 2.5 mg/1 tableta+ 2.5 mg/1 tableta film tableta
sanofi d.o.o. - felodipin, ramipril - film tableta - 2.5 mg/1 tableta+ 2.5 mg/1 tableta - 1 film tableta sadrži: 2,5 mg ramipril 2,5 mg felodipin
triapin 5 mg/1 tableta+ 5 mg/1 tableta film tableta
sanofi d.o.o. - felodipin, ramipril - film tableta - 5 mg/1 tableta+ 5 mg/1 tableta - 1 film tableta sadrži: 5 mg ramipril 5 mg felodipin
zankaf 500 mg/1 tableta+ 50 mg/1 tableta tableta
evropa lijek pharma d.o.o. - acetilsalicilna kiselina, kofein - tableta - 500 mg/1 tableta+ 50 mg/1 tableta - 1 tableta sadrži: 500 mg acetilsalicilne kiseline i 50 mg kofeina
zankaf 500 mg/1 tableta+ 50 mg/1 tableta tableta
evropa lijek pharma d.o.o. - acetilsalicilna kiselina, kofein - tableta - 500 mg/1 tableta+ 50 mg/1 tableta - 1 tableta sadrži: 500 mg acetilsalicilne kiseline i 50 mg kofeina
tigeciklin sk 50mg prašak za rastvor za infuziju
druŠtvo sa ograniČenom odgovornoŠĆu "inmed" podgorica - tigeciklin - prašak za rastvor za infuziju - 50mg
blincyto
amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
kyprolis
amgen europe b.v. - carfilzomib - multipli mijelom - antineoplastična sredstva - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
tysabri
biogen netherlands b.v. - natalizumab - multipla skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
atenolol remedica 50 mg/1 tableta film tableta
farmalogist allbix d.o.o. bijeljina - atenolol - film tableta - 50 mg/1 tableta - 1 film tableta sadrži: 50 mg atenolola
atenolol remedica 100 mg/1 tableta film tableta
farmalogist allbix d.o.o. bijeljina - atenolol - film tableta - 100 mg/1 tableta - 1 film tableta sadrži: 100 mg atenolol